Gwak G-Y, Koh K C, Kim H-Y
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-Gu, Seoul, South Korea.
Clin Exp Rheumatol. 2007 Nov-Dec;25(6):888-9.
A 66-year-old female patient with rheumatoid arthritis, who had been HBsAg-negative and anti-HBs-positive, developed hepatic dysfunction following low-dose methotrexate therapy. Serologic testing for HBsAg, HBeAg, IgM HBc and HBV DNA were positive. Despite antiviral therapy with lamivudine, the hepatic condition gradually deteriorated until the patient died. Since HBV replication persists in the liver even in individuals with resolved HBV infection (i.e., HBsAg-negative, anti-HBs-positive), HBV reactivation may occur in these patients with immunosuppression. Therefore, especially in endemic areas, all patients being considered for immunosuppressive therapy should be closely monitored with liver function tests and evaluated for HBV reappearance even when HBsAg-negative.
一名66岁的类风湿关节炎女性患者,既往乙肝表面抗原(HBsAg)阴性且乙肝表面抗体(抗-HBs)阳性,在接受小剂量甲氨蝶呤治疗后出现肝功能障碍。HBsAg、乙肝e抗原(HBeAg)、IgM型乙肝核心抗体(IgM HBc)及乙肝病毒脱氧核糖核酸(HBV DNA)的血清学检测均呈阳性。尽管使用拉米夫定进行抗病毒治疗,但患者的肝脏状况仍逐渐恶化,直至死亡。由于即使在乙肝病毒感染已清除的个体(即HBsAg阴性、抗-HBs阳性)中,乙肝病毒仍在肝脏中持续复制,因此这些免疫抑制患者可能会发生乙肝病毒再激活。所以,尤其是在乙肝流行地区,所有考虑接受免疫抑制治疗的患者都应通过肝功能检查进行密切监测,即使HBsAg为阴性,也需评估乙肝病毒是否再次出现。